Phase 1: Randomized Evaluation of a System to Deliver Mobile Cognitive Behavioral Therapy (P1RESPECT)
Primary Purpose
Pain, Postoperative, Analgesics, Opioid
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
InCaveo's EOA system with integrated mobile CBT
Sponsored by
About this trial
This is an interventional prevention trial for Pain, Postoperative focused on measuring pain
Eligibility Criteria
Inclusion Criteria:
- Patient has a Pain Catastrophizing Score >16
- 55 years of age and older.
- English speaking.
- Has a smartphone (iPhone).
- Able to swallow oral medications.
- No continuous daily opioid as defined as more than 15 days in the 30 days before surgery.
- Undergoing TKR surgery.
- Patients who are willing and able to comply with scheduled visits and study procedures.
Exclusion Criteria:
- Diagnosed with Opioid Use Disorder (OUD).
- Actively using illicit drugs.
- Allergy to opioids
- Older than 85 years
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
InCaveo EOA System
Control Group-usual care with pill bottles
Arm Description
InCaveo EOA System (including integrated CBT but without tapering) group
UCPB group-usual care with pill bottles
Outcomes
Primary Outcome Measures
Pain Catastrophizing Scale (PCS)
A measure of the extent of catastrophizing
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04836169
Brief Title
Phase 1: Randomized Evaluation of a System to Deliver Mobile Cognitive Behavioral Therapy
Acronym
P1RESPECT
Official Title
Phase 1: Randomized Evaluation of a System to Deliver Mobile Cognitive Behavioral Therapy to Lower Pain Catastrophizing Scores
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
October 2021 (Anticipated)
Primary Completion Date
April 2022 (Anticipated)
Study Completion Date
May 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
InCaveo
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The clinical study described in this Clinical Investigation Plan (CIP) will be completed in two stages, Phase I and Phase II. The results of Phase I will confirm patient use of InCaveo's EOA system with integrated mobile CBT but without tapering to improve The Pain Catastrophizing Scale (PCS) scores, and secondarily scores on the VNS pain scale, the Tampa Scale of Kinesiophobia (TSK), and patient satisfaction scores in the subacute period (defined as 2 weeks to 3 months post TKR). Statistically significant positive results on the Pain Catastrophizing Scale (PCS) will trigger phase 2. Phase 1 will also inform the detailed conditions and patient management algorithms for Phase II.
Detailed Description
The InCaveo End Opioid Addiction (EOA) System is an integrated pain management therapeutic and opioid tapering system providing alternate treatment options via self-service Cognitive Behavior Therapy (CBT) built into a mobile software app, patient medication usage, and tracking of patient PROs. It is designed to be used alongside Usual Standard of Care using Pill Bottles or to simplify, Usual Care with Pill Bottles (UCPB) treatment practices. The InCaveo EOA System is designed to improve a set of patient outcome measures, primarily Pain Catastrophizing Scale (PCS) and secondarily the Visual Numeric Pain (VNS), Kinesiophobia (TSK) and satisfaction scores while facilitating the ability of patients to taper off their pain medication faster than through the use of USPB in the management of post-operative pain. In order to reduce confounding variables, the study will focus on pain management following a single surgical procedure: Total Knee Replacement (TKR) surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Analgesics, Opioid
Keywords
pain
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized parallel-group
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
InCaveo EOA System
Arm Type
Experimental
Arm Description
InCaveo EOA System (including integrated CBT but without tapering) group
Arm Title
Control Group-usual care with pill bottles
Arm Type
No Intervention
Arm Description
UCPB group-usual care with pill bottles
Intervention Type
Device
Intervention Name(s)
InCaveo's EOA system with integrated mobile CBT
Intervention Description
integrated pain management therapeutic and tapering system including a software apt that manages and tracks patient-reported outcomes, including pain levels, medication use, quality of life
Primary Outcome Measure Information:
Title
Pain Catastrophizing Scale (PCS)
Description
A measure of the extent of catastrophizing
Time Frame
60 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient has a Pain Catastrophizing Score >16
55 years of age and older.
English speaking.
Has a smartphone (iPhone).
Able to swallow oral medications.
No continuous daily opioid as defined as more than 15 days in the 30 days before surgery.
Undergoing TKR surgery.
Patients who are willing and able to comply with scheduled visits and study procedures.
Exclusion Criteria:
Diagnosed with Opioid Use Disorder (OUD).
Actively using illicit drugs.
Allergy to opioids
Older than 85 years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cynthia Harris, BS
Phone
8326776747
Email
cindy@clinregconsult.com
First Name & Middle Initial & Last Name or Official Title & Degree
Michael A Daniel, MBA
Phone
4154070223
Email
madaniel@clinregconsult.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hoyman Hong, MD
Organizational Affiliation
InCaveo
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Phase 1: Randomized Evaluation of a System to Deliver Mobile Cognitive Behavioral Therapy
We'll reach out to this number within 24 hrs